Regulatory asymmetry in Alzheimer's disease care

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F25%3A10498043" target="_blank" >RIV/00064203:_____/25:10498043 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/25:10498043

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=1yhhHe2WLt" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=1yhhHe2WLt</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S0140-6736(25)00907-9" target="_blank" >10.1016/S0140-6736(25)00907-9</a>

Result language

angličtina

Original language name

Regulatory asymmetry in Alzheimer's disease care

Original language description

We welcome the European Commission&apos;s recent approval of lecanemab for the treatment of Alzheimer&apos;s disease. This approval reflects growing recognition that disease-modifying treatments, despite their limitations, offer meaningful benefits. Both lecanemab and donanemab have shown that amyloid lowering can slow clinical progression in mild cognitive impairment or mild dementia of the Alzheimer&apos;s type.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

The Lancet

ISSN

0140-6736

e-ISSN

1474-547X

Volume of the periodical

405

Issue of the periodical within the volume

10492

Country of publishing house

GB - UNITED KINGDOM

Number of pages

2

Pages from-to

1812-1813

UT code for WoS article

001509990600014

EID of the result in the Scopus database

2-s2.0-105005498384